China AI: Bernstein sees chipmakers benefiting from Nvidia scrutiny
On Monday, Stifel analysts adjusted their outlook on Revolution (NASDAQ:RVMD) shares, reducing the price target to $64 from $78 while still endorsing the stock with a Buy rating. According to InvestingPro data, analyst targets for RVMD range from $59 to $87, with the stock currently trading at $35.36, suggesting significant upside potential despite recent price weakness. The firm’s analysis focused on the valuation of Revolution’s various programs, particularly daraxonrasib, also known as RMC-6236 or RAS-multi. This drug is perceived to be a significant factor in the company’s near-term stock performance due to its potential in four key markets: second-line pancreatic ductal adenocarcinoma (PDAC), first-line PDAC, second-line non-small cell lung cancer (NSCLC), and first-line NSCLC.
The Stifel team evaluated the net present value (NPV) of each market opportunity for daraxonrasib under different scenarios. They considered factors such as intellectual property (IP) longevity, competitive landscape, incremental risk adjustment (IRA), and historical data from oncology drug launches. Their findings suggest that the combined value of daraxonrasib’s market opportunities could be worth over $69 per share. InvestingPro analysis shows the company maintains a strong financial position with a current ratio of 14.2, indicating robust liquidity to support its drug development programs.
However, after a thorough review of their financial model, Stifel analysts have incorporated a more conservative stance on the impact of competition and the expected duration of therapy. The revised approach led them to lower their target price to $64. The Stifel team’s commentary indicates that while other programs like colorectal cancer (CRC) and zoldonrasib are also of importance, the market’s focus on daraxonrasib is likely to be the main driver of Revolution’s stock in the near term.
Stifel’s analysis provides an in-depth look at the potential of Revolution’s leading drug candidate and reflects adjustments based on the current oncology market dynamics. The firm’s maintained Buy rating suggests they still see significant potential in Revolution’s stock despite the lowered price target. Revolution’s shares will continue to be watched closely by investors as the company progresses with its drug development and commercialization efforts. While the company isn’t currently profitable, InvestingPro data reveals it holds more cash than debt on its balance sheet, providing financial flexibility for its development pipeline. Discover more insights and 6 additional ProTips for RVMD in the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, Revolution Medicines reported its fourth-quarter financial results, highlighting a net loss of $194.6 million, which increased from the $161.5 million loss in Q4 2023. Despite the losses, the company maintains a strong cash position with $2.3 billion in cash and investments, supported by $823 million from an equity offering. Analysts at H.C. Wainwright adjusted their price target for Revolution Medicines to $73, maintaining a Buy rating, while Needham analysts lowered their target to $59, also keeping a Buy rating. The adjustments followed the company’s reported loss per share of $1.12, which was larger than the consensus estimate of $0.99. Revolution Medicines has announced plans for two additional registrational trials for its investigational drug, daraxonrasib, targeting pancreatic ductal adenocarcinoma. Needham analysts anticipate a positive market response to these expansions, particularly in the adjuvant setting for PDAC. The company projects a GAAP net loss between $840 million and $900 million for 2025, reflecting increased expenses associated with its clinical development programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.